retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Today, we shared new data from two trials of retatrutide, our investigational agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide for Weight Loss: What

Higher IGF-1 signaling has been associated in population studies with increased risk of certain cancers, including breast, prostate, and colorectal cancers

Orforglipron is not suitable for you if you: Are pregnant or breastfeeding Have a personal or family history of a rare type of thyroid cancer called medullary thyroid carcinoma Have a history of multiple endocrine neoplasia syndrome type 2 (MEN 2) Have had inflammation of your pancreas (pancreatitis) in the past Have certain gastrointestinal diseases How to take orforglipron Always take any medicine exactly as your doctor tells you to

Individuals with long-standing shoulder, pec, knee, hip, or back issues generally do not report significant improvements

Wang Z, Fang G, Gao Z, Liao Y, Gong C, Kim M, Chang GE, Feng S, Xu T, Liu T, Chen YC

L- ,